Modafinil vs PT-141
FDA Approved vs FDA Approved
monitor Mechanism-based · 60% Both Modafinil and PT-141 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Modafinil PT-141
Weight 273.35 Da —
Half-life ~12-15 hours ~2.7 hours
Type Diphenylmethylsulfinylacetamide (C15H15NO2S) Melanocortin receptor agonist
Key Benefits
Modafinil
01 Sustained wakefulness and alertness for 10-15 hours without the jitteriness of traditional stimulants
02 Enhanced executive function, working memory, and decision-making under fatigue
03 Improved focus and concentration during prolonged cognitive tasks
04 Reduced impulsivity and improved task completion in sleep-deprived individuals
05 Low abuse potential relative to amphetamine-class stimulants (Schedule IV)
06 Minimal impact on normal sleep architecture when taken in the morning
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Modafinil
100-200 mg/day / Once daily (morning)
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Modafinil
Headache (most frequently reported side effect, often dose-dependent)
Insomnia (particularly if taken too late in the day)
Anxiety and nervousness
Appetite suppression and mild nausea
Dry mouth
Dizziness
Gastrointestinal discomfort (diarrhea, abdominal pain)
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Known hypersensitivity to modafinil or armodafinil
History of Stevens-Johnson Syndrome, TEN, or DRESS with prior modafinil/armodafinil use
Severe hepatic impairment (dose reduction required in moderate impairment)
Unstable angina or recent myocardial infarction
Left ventricular hypertrophy or clinically significant mitral valve prolapse with prior stimulant use
Pregnancy (limited human data; animal studies show teratogenicity at high doses)
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Modafinil PT-141
Status FDA Approved FDA Approved
References 5 studies 4 studies
Latest — 2022
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.